Clinical study of topical nanoliposome formulation of ruxolitinib 1.5% in treatment of eczema
Phase 2
Recruiting
- Conditions
- Atopic dermatitis.Atopic dermatitis
- Registration Number
- IRCT20161207031288N9
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Case of mild to moderate atopic dermatitis (SCORAD between 4 and 12)
Older than 18 years
Signing informed consent to participate in the study
Having a negative pregnancy test
Willingness to actively participate in the study
Exclusion Criteria
Pregnancy and lactation
Use of any topical corticosteroids in the last 14 days
Drug and alcohol addiction
Use of oral corticosteroids or other immunosuppressive drugs in the last 28 days
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of lesions of atopic dermatitis according to Scorad score. Timepoint: Before intervention, and 2 and 4 weeks after than. Method of measurement: Clinical exam.
- Secondary Outcome Measures
Name Time Method Dermal erythema variations. Timepoint: Before intervention, and 2 and 4 weeks after than. Method of measurement: Mexameter.